Figure 1

Plots of sensitivities to dacetuzumab of each of the 31 cell lines used in this case study. A plot of the dacetuzumab IC25 (in μg/mL) of each of the 31 cell lines used in the dacetuzumab sensitivity case study, taken from results originally reported by Burington et al (Burington, B., Yue, P., Shi, X., et al: CD40 Pathway Activation Status Predicts the Anti-Tumor Activity of CD40 Therapy in Diffuse Large B-Cell Lymphoma, submitted). The IC25 is defined as the dosage required to kill 25% of the cells. A maximum dosage of 1 μg/mL was administered to each of the cell lines. We define a cell line as sensitive if the IC25 is below 0.4 μg/mL, semi-sensitive if the IC25 is between 0.4 and 1 μg/mL, and resistant if the maximum dosage was insufficient to kill 25% of the cells.